Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.52
MYGN's Cash-to-Debt is ranked lower than
59% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.13 vs. MYGN: 1.52 )
Ranked among companies with meaningful Cash-to-Debt only.
MYGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.52  Med: No Debt Max: No Debt
Current: 1.52
Equity-to-Asset 0.64
MYGN's Equity-to-Asset is ranked higher than
55% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. MYGN: 0.64 )
Ranked among companies with meaningful Equity-to-Asset only.
MYGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.64  Med: 0.88 Max: 0.94
Current: 0.64
0.64
0.94
Debt-to-Equity 0.13
MYGN's Debt-to-Equity is ranked higher than
69% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.35 vs. MYGN: 0.13 )
Ranked among companies with meaningful Debt-to-Equity only.
MYGN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.01 Max: 0.13
Current: 0.13
0
0.13
Debt-to-EBITDA 1.00
MYGN's Debt-to-EBITDA is ranked higher than
65% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.62 vs. MYGN: 1.00 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MYGN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1  Med: 1.02 Max: 1.02
Current: 1
1
1.02
Interest Coverage 9.30
MYGN's Interest Coverage is ranked lower than
67% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.25 vs. MYGN: 9.30 )
Ranked among companies with meaningful Interest Coverage only.
MYGN' s Interest Coverage Range Over the Past 10 Years
Min: 8.23  Med: No Debt Max: No Debt
Current: 9.3
Piotroski F-Score: 4
Altman Z-Score: 4.17
Beneish M-Score: -3.36
WACC vs ROIC
3.20%
3.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 6.39
MYGN's Operating Margin % is ranked higher than
60% of the 229 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. MYGN: 6.39 )
Ranked among companies with meaningful Operating Margin % only.
MYGN' s Operating Margin % Range Over the Past 10 Years
Min: 6.39  Med: 35.81 Max: 39.24
Current: 6.39
6.39
39.24
Net Margin % 2.81
MYGN's Net Margin % is ranked higher than
58% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. MYGN: 2.81 )
Ranked among companies with meaningful Net Margin % only.
MYGN' s Net Margin % Range Over the Past 10 Years
Min: 2.81  Med: 22.63 Max: 42
Current: 2.81
2.81
42
ROE % 2.90
MYGN's ROE % is ranked higher than
56% of the 222 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.01 vs. MYGN: 2.90 )
Ranked among companies with meaningful ROE % only.
MYGN' s ROE % Range Over the Past 10 Years
Min: 2.86  Med: 18.28 Max: 30.71
Current: 2.9
2.86
30.71
ROA % 1.83
MYGN's ROA % is ranked higher than
61% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.54 vs. MYGN: 1.83 )
Ranked among companies with meaningful ROA % only.
MYGN' s ROA % Range Over the Past 10 Years
Min: 1.83  Med: 16.98 Max: 28.73
Current: 1.83
1.83
28.73
ROC (Joel Greenblatt) % 45.64
MYGN's ROC (Joel Greenblatt) % is ranked higher than
82% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.64 vs. MYGN: 45.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MYGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 45.64  Med: 251.31 Max: 362.64
Current: 45.64
45.64
362.64
3-Year Revenue Growth Rate 4.10
MYGN's 3-Year Revenue Growth Rate is ranked lower than
56% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. MYGN: 4.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MYGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.6  Med: 20.1 Max: 45.7
Current: 4.1
1.6
45.7
3-Year EBITDA Growth Rate -27.40
MYGN's 3-Year EBITDA Growth Rate is ranked lower than
87% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.90 vs. MYGN: -27.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MYGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -27.4  Med: 7.25 Max: 48.5
Current: -27.4
-27.4
48.5
3-Year EPS without NRI Growth Rate -47.80
MYGN's 3-Year EPS without NRI Growth Rate is ranked lower than
93% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. MYGN: -47.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MYGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -47.8  Med: 3.3 Max: 68.8
Current: -47.8
-47.8
68.8
GuruFocus has detected 8 Warning Signs with Myriad Genetics Inc MYGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MYGN's 30-Y Financials

Financials (Next Earnings Date: 2017-11-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

MYGN Guru Trades in Q3 2016

Ron Baron 40,000 sh (New)
Paul Tudor Jones 31,742 sh (+124.06%)
Jim Simons 2,931,674 sh (+120.05%)
Lee Ainslie 152,050 sh (+61.98%)
Joel Greenblatt 421,728 sh (+16.88%)
Ken Fisher 92,381 sh (+0.16%)
First Eagle Investment Sold Out
Mario Gabelli Sold Out
Chuck Royce 90,369 sh (-90.36%)
» More
Q4 2016

MYGN Guru Trades in Q4 2016

Ron Baron 80,000 sh (+100.00%)
Paul Tudor Jones 47,033 sh (+48.17%)
Lee Ainslie 190,720 sh (+25.43%)
Chuck Royce Sold Out
Jim Simons 2,686,174 sh (-8.37%)
Joel Greenblatt 289,042 sh (-31.46%)
Ken Fisher 59,731 sh (-35.34%)
» More
Q1 2017

MYGN Guru Trades in Q1 2017

Ron Baron 136,500 sh (+70.63%)
Joel Greenblatt 349,262 sh (+20.83%)
Ken Fisher 61,011 sh (+2.14%)
Lee Ainslie Sold Out
Paul Tudor Jones 19,700 sh (-58.11%)
Jim Simons 534,700 sh (-80.09%)
» More
Q2 2017

MYGN Guru Trades in Q2 2017

Ron Baron 215,500 sh (+57.88%)
Ken Fisher 61,011 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Joel Greenblatt 258,812 sh (-25.90%)
» More
» Details

Insider Trades

Latest Guru Trades with MYGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Reduce -25.90%0.02%$17.61 - $26.47 $ 34.3963%258,812
Ron Baron 2017-06-30 Add 57.88%0.01%$17.61 - $26.47 $ 34.3963%215,500
Joel Greenblatt 2017-03-31 Add 20.83%0.02%$15.4 - $19.67 $ 34.3994%349,262
Ron Baron 2017-03-31 Add 70.63%$15.4 - $19.67 $ 34.3994%136,500
Ken Fisher 2017-03-31 Add 2.14%$15.4 - $19.67 $ 34.3994%61,011
Joel Greenblatt 2016-12-31 Reduce -31.46%0.03%$16.26 - $21.35 $ 34.3990%289,042
Ron Baron 2016-12-31 Add 100.00%0.01%$16.26 - $21.35 $ 34.3990%80,000
Ken Fisher 2016-12-31 Reduce -35.34%$16.26 - $21.35 $ 34.3990%59,731
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:TSE:4544, BSP:DASA3, SZSE:300244, SZSE:300463, SHSE:603658, NAS:NEOG, BSP:FLRY3, SZSE:300482, NAS:QDEL, NAS:FMI, NAS:VREX, SHSE:603108, NAS:AXDX, NAS:MEDP, SHSE:600055, NAS:GHDX, NAS:BEAT, SZSE:300685, SZSE:300439, NAS:ALOG » details
Traded in other countries:MYD.Germany,
Headquarter Location:USA
Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease or tailor treatment for already diagnosed patients. The firm produces myRisk, a 28-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysis CDx, GeneSight, Vectra DA, and Prolaris. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.

Top Ranked Articles about Myriad Genetics Inc

GeneSight® Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodiazepine Use
Myriad’s BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Lynparza® (olaparib) in Metastatic Breast Cancer
Myriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Month
Myriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Month
Myriad Genetics Announces Positive Data Supporting New riskScore™ Test at the 36th Annual Conference of the National Society of Genetic Counselors
Myriad Genetics to Present Three Studies at the 2017 National Society of Genetic Counselors Annual Conference
Hereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month
Myriad Launches riskScore™ Beginning the Next Epoch in Hereditary Cancer Testing
Myriad Genetics to Present at the 2017 Morgan Stanley Global Healthcare Conference
Myriad Genetics to Present at the 2017 Wells Fargo Healthcare Conference

Ratios

vs
industry
vs
history
PE Ratio 107.46
MYGN's PE Ratio is ranked lower than
94% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. MYGN: 107.46 )
Ranked among companies with meaningful PE Ratio only.
MYGN' s PE Ratio Range Over the Past 10 Years
Min: 9.06  Med: 19.68 Max: 116.06
Current: 107.46
9.06
116.06
Forward PE Ratio 33.00
MYGN's Forward PE Ratio is ranked lower than
76% of the 33 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.26 vs. MYGN: 33.00 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 107.46
MYGN's PE Ratio without NRI is ranked lower than
94% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.88 vs. MYGN: 107.46 )
Ranked among companies with meaningful PE Ratio without NRI only.
MYGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.06  Med: 18.88 Max: 116.06
Current: 107.46
9.06
116.06
Price-to-Owner-Earnings 99.41
MYGN's Price-to-Owner-Earnings is ranked lower than
86% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.21 vs. MYGN: 99.41 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MYGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.71  Med: 24.58 Max: 115.39
Current: 99.41
9.71
115.39
PB Ratio 3.01
MYGN's PB Ratio is ranked higher than
58% of the 223 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. MYGN: 3.01 )
Ranked among companies with meaningful PB Ratio only.
MYGN' s PB Ratio Range Over the Past 10 Years
Min: 1.46  Med: 3.55 Max: 8.23
Current: 3.01
1.46
8.23
PS Ratio 3.08
MYGN's PS Ratio is ranked higher than
55% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. MYGN: 3.08 )
Ranked among companies with meaningful PS Ratio only.
MYGN' s PS Ratio Range Over the Past 10 Years
Min: 1.48  Med: 4.34 Max: 14.75
Current: 3.08
1.48
14.75
Price-to-Free-Cash-Flow 23.66
MYGN's Price-to-Free-Cash-Flow is ranked higher than
51% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.99 vs. MYGN: 23.66 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MYGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.6  Med: 16.4 Max: 44.47
Current: 23.66
7.6
44.47
Price-to-Operating-Cash-Flow 22.31
MYGN's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. MYGN: 22.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MYGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.21  Med: 15.46 Max: 44
Current: 22.31
7.21
44
EV-to-EBIT 46.18
MYGN's EV-to-EBIT is ranked lower than
79% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.52 vs. MYGN: 46.18 )
Ranked among companies with meaningful EV-to-EBIT only.
MYGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -102.5  Med: 10.8 Max: 52.4
Current: 46.18
-102.5
52.4
EV-to-EBITDA 23.60
MYGN's EV-to-EBITDA is ranked lower than
60% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.06 vs. MYGN: 23.60 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -161.3  Med: 9.8 Max: 45.9
Current: 23.6
-161.3
45.9
EV-to-Revenue 3.03
MYGN's EV-to-Revenue is ranked higher than
59% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. MYGN: 3.03 )
Ranked among companies with meaningful EV-to-Revenue only.
MYGN' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.5  Med: 3.6 Max: 14.5
Current: 3.03
1.5
14.5
Shiller PE Ratio 25.70
MYGN's Shiller PE Ratio is ranked higher than
77% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 49.53 vs. MYGN: 25.70 )
Ranked among companies with meaningful Shiller PE Ratio only.
MYGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 12.33  Med: 44.88 Max: 2553
Current: 25.7
12.33
2553
Current Ratio 1.46
MYGN's Current Ratio is ranked lower than
76% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. MYGN: 1.46 )
Ranked among companies with meaningful Current Ratio only.
MYGN' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 5.22 Max: 17.26
Current: 1.46
1.46
17.26
Quick Ratio 1.26
MYGN's Quick Ratio is ranked lower than
73% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. MYGN: 1.26 )
Ranked among companies with meaningful Quick Ratio only.
MYGN' s Quick Ratio Range Over the Past 10 Years
Min: 1.26  Med: 5.22 Max: 17.26
Current: 1.26
1.26
17.26
Days Inventory 99.34
MYGN's Days Inventory is ranked lower than
55% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.37 vs. MYGN: 99.34 )
Ranked among companies with meaningful Days Inventory only.
MYGN' s Days Inventory Range Over the Past 10 Years
Min: 22.14  Med: 48.67 Max: 99.34
Current: 99.34
22.14
99.34
Days Sales Outstanding 49.97
MYGN's Days Sales Outstanding is ranked higher than
69% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.49 vs. MYGN: 49.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.41  Med: 46.88 Max: 66.6
Current: 49.97
38.41
66.6
Days Payable 46.88
MYGN's Days Payable is ranked lower than
61% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. MYGN: 46.88 )
Ranked among companies with meaningful Days Payable only.
MYGN' s Days Payable Range Over the Past 10 Years
Min: 46.88  Med: 75.16 Max: 280.85
Current: 46.88
46.88
280.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.50
MYGN's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.50 vs. MYGN: 2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: -5.8 Max: 5.9
Current: 2.5
-13.6
5.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.10
MYGN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
85% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. MYGN: 1.10 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MYGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.82  Med: 1.14 Max: 23.09
Current: 1.1
0.82
23.09
Price-to-Median-PS-Value 0.71
MYGN's Price-to-Median-PS-Value is ranked higher than
70% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. MYGN: 0.71 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.53  Med: 1.28 Max: 9.59
Current: 0.71
0.53
9.59
Earnings Yield (Greenblatt) % 2.17
MYGN's Earnings Yield (Greenblatt) % is ranked higher than
63% of the 246 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.72 vs. MYGN: 2.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.1  Med: 7.2 Max: 22.7
Current: 2.17
-3.1
22.7
Forward Rate of Return (Yacktman) % -3.04
MYGN's Forward Rate of Return (Yacktman) % is ranked lower than
80% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.99 vs. MYGN: -3.04 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MYGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -19.9  Med: 3.3 Max: 29.8
Current: -3.04
-19.9
29.8

More Statistics

Revenue (TTM) (Mil) $771.40
EPS (TTM) $ 0.32
Beta0.13
Short Percentage of Float27.32%
52-Week Range $15.15 - 37.30
Shares Outstanding (Mil)69.21

Analyst Estimate

Jun18 Jun19 Jun20
Revenue (Mil $) 771 809 851
EPS ($) 1.05 1.18 1.32
EPS without NRI ($) 1.05 1.18 1.32
EPS Growth Rate
(Future 3Y To 5Y Estimate)
8.20%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}